Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of “Buy” by Analysts

Vaxcyte, Inc. (NASDAQ:PCVXGet Free Report) has earned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the stock in the last year is $145.71.

Several brokerages have weighed in on PCVX. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th.

Get Our Latest Analysis on PCVX

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the transaction, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $17,208,443.70. The trade was a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total transaction of $457,450.00. Following the completion of the sale, the senior vice president now directly owns 28,697 shares of the company’s stock, valued at $2,625,488.53. The trade was a 14.84 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 70,982 shares of company stock worth $6,341,485. 3.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PCVX. Riverview Trust Co acquired a new position in shares of Vaxcyte during the third quarter worth $27,000. Blue Trust Inc. lifted its holdings in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. purchased a new position in Vaxcyte in the 3rd quarter valued at about $92,000. Finally, Signaturefd LLC grew its stake in shares of Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after acquiring an additional 358 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Up 2.0 %

PCVX opened at $86.51 on Friday. The firm has a market cap of $10.78 billion, a P/E ratio of -18.81 and a beta of 0.98. The business’s fifty day simple moving average is $87.46 and its 200 day simple moving average is $94.42. Vaxcyte has a 52 week low of $58.10 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVXGet Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the firm earned ($0.91) EPS. As a group, equities analysts expect that Vaxcyte will post -4.21 EPS for the current fiscal year.

About Vaxcyte

(Get Free Report

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Featured Articles

Analyst Recommendations for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.